Pneumovax 23 Market Report 2026

Pneumovax 23 Market Overview

• The Pneumovax 23 market growth in the historic period has been driven by expansion of national immunization guidelines, rising incidence of pneumococcal infections in elderly populations • Market expansion is supported by increasing investments in adult vaccination programs, rising focus on infectious disease prevention • Growth Driver: Rising Global Incidence Of Pneumococcal Diseases To Drive Demand For Pneumovax 23 Vaccine • North America was the largest region in 2025.

What Is Covered Under Pneumovax 23 Market?

Pneumovax 23 is a vaccine that protects against 23 types of pneumococcal bacteria, which can cause serious illnesses such as pneumonia, meningitis, and bloodstream infections. It is primarily used for older adults and individuals with certain medical conditions to prevent invasive pneumococcal diseases. The vaccine stimulates the immune system to recognize and fight these specific strains of bacteria, providing long-term protection. The main formulations of pneumovax 23 are pneumococcal polysaccharide vaccine (PPV), and pneumococcal conjugate vaccine (PCV). Pneumococcal polysaccharide vaccine (PPV) is a vaccine designed to protect against multiple strains of pneumococcal bacteria using polysaccharides from bacterial capsules. Pneumovax 23 is a widely used pneumococcal polysaccharide vaccine that protects against 23 strains of pneumococcal bacteria. For clinical indications such as pneumococcal disease prevention and utilized by end users such as hospitals, clinics, ambulatory surgical centers, and pharmacies.

What Is The Pneumovax 23 Market Growth Forecast?

The growth in the forecast period can be attributed to increasing investments in adult vaccination programs, rising focus on infectious disease prevention, expansion of pharmacy-based immunization services, growing demand for long-term vaccine protection, advancements in vaccine storage and distribution. Major trends in the forecast period include increasing focus on adult and geriatric immunization programs, rising demand for pneumococcal disease prevention, growing adoption of preventive vaccination strategies, expansion of public health immunization campaigns, enhanced cold-chain vaccine management.

Global Pneumovax 23 Market Segmentation

1) By Formulation: Pneumococcal Polysaccharide Vaccine (PPV), Pneumococcal Conjugate Vaccine (PCV) 2) By Clinical Indication: Pneumococcal Disease Prevention 3) By End User: Hospitals, Clinics, Ambulatory Surgical Centers, Pharmacies

What Are The Drivers Of The Pneumovax 23 Market?

The increasing incidence of pneumococcal diseases is expected to propel the growth of the pneumovax 23 market going forward. Pneumococcal diseases are infections caused by the bacterium streptococcus pneumoniae, commonly known as pneumococcus, which can lead to various health issues, from mild conditions such as sinusitis and otitis media to severe illnesses such as pneumonia and meningitis, potentially requiring hospitalization. The increasing incidence of pneumococcal diseases can be attributed to factors such as reduced vaccination coverage during the COVID-19 pandemic, heightened risk among individuals with chronic health conditions, and the resurgence of respiratory infections following the easing of social restrictions. Pneumovax 23 prevents pneumococcal diseases by immunizing against 23 strains of streptococcus pneumoniae, reducing the risk of infections such as pneumonia, meningitis, and bacteremia. For instance, in June 2025, according to the Office for Health Improvement and Disparities, a UK-based government body focused on public health and reducing health inequalities, in the financial year ending 2024, emergency hospital admissions for pneumonia in England rose by 16% compared to the prior year, reaching a rate of 430 per 100,000 people and accounting for approximately 252,912 admissions. Therefore, the increasing incidence of pneumococcal diseases globally is driving the growth of the pneumovax 23 industry. The increasing rate of urbanization is anticipated to drive the growth of the pneumovax 23 market in the future. Growing urbanization is driven by factors such as industrialization, which creates improved employment opportunities in cities, better access to education and healthcare, and the overall allure of urban lifestyles that attract individuals from rural areas seeking a higher standard of living. Urban populations typically have greater access to health education and awareness campaigns. This can lead to higher vaccination rates as people recognize the importance of preventing pneumococcal diseases. For instance, in April 2023, according to a report published by the World Bank Group, a US-based financial institution, about 56% of the world's population, or 4.4 billion people, live in urban areas, a trend projected to continue with the urban population expected to nearly double by 2050, reaching nearly 70%. Additionally, urban land consumption exceeds population growth by up to 50%, adding an estimated 1.2 million square kilometers of new urban area by 2030. Therefore, the rise in urbanization is driving the growth of the pneumovax 23 industry. The expansion of government immunization initiatives is expected to propel the growth of the pneumovax 23 market going forward. Government immunization initiatives are organized by national or local governments to promote and provide vaccines to populations to prevent vaccine-preventable diseases, increase vaccination coverage, and improve public health outcomes through programs that may include routine immunization schedules, vaccination campaigns, and public awareness efforts. Expanding government immunization initiatives are driven by the need to improve public health outcomes, increase vaccination coverage, and address gaps in immunization that have emerged due to factors such as the COVID-19 pandemic, ensuring equitable access to vaccines for all populations to prevent the spread of infectious diseases. Government immunization initiatives boost Pneumovax 23 by increasing access to the vaccine, promoting public awareness, and driving higher vaccination rates to prevent pneumococcal diseases. For instance, in July 2024, according to the Gavi, a Switzerland-based vaccine alliance, reported that in 2023, about 69 million children received Gavi-supported routine immunizations, close to the highest annual totals ever. By 2024, over 72 million children in lower-income countries were vaccinated with Gavi support, showing continued scale-up. Therefore, expanding government immunization initiatives is driving the growth of the pneumovax 23 industry.

Key Players In The Global Pneumovax 23 Market

Major companies operating in the pneumovax 23 market are Merck & Co. Inc. (Merck Sharp & Dohme Corp.)

Regional Insights

North America was the largest region in the pneumovax 23 market in 2025. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Pneumovax 23 Market?

The pneumovax 23 market consists of the sales of pneumovax 23 vaccine (the primary 23-valent pneumococcal polysaccharide vaccine). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Pneumovax 23 Market Report 2026?

The pneumovax 23 market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the pneumovax 23 industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.